[1]邵毅,郭楚祎,石文卿.亚洲春季角结膜炎的诊疗规范： 2022年亚洲专家共识解读[J].眼科新进展,2023,43(3):169-172.[doi:10.13389/j.cnki.rao.2023.0034]
　SHAO Yi,GUO Chuyi,SHI Wenqing.Guide to diagnosis and treatment of vernal keratoconjunctivitis in Asia: interpretation of the consensus of Asian experts in 2022[J].Recent Advances in Ophthalmology,2023,43(3):169-172.[doi:10.13389/j.cnki.rao.2023.0034]
点击复制

亚洲春季角结膜炎的诊疗规范： 2022年亚洲专家共识解读/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
43卷
期数:
2023年3期
页码:
169-172
栏目:
述评
出版日期:
2023-03-05

文章信息/Info

Title:
Guide to diagnosis and treatment of vernal keratoconjunctivitis in Asia: interpretation of the consensus of Asian experts in 2022
作者:
邵毅; 郭楚祎; 石文卿
330006　江西省南昌市，南昌大学第一附属医院眼科
Author(s):
SHAO Yi; GUO Chuyi;  SHI Wenqing
Department of Ophthalmology,the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China
关键词:
春季角结膜炎; 诊断和治疗; 指南解读
Keywords:
vernal keratoconjunctivitis;  diagnosis and treatment;  guide interpretation
分类号:
R777.31
DOI:
10.13389/j.cnki.rao.2023.0034
文献标志码:
A
摘要:
春季角结膜炎(VKC)是一种反复发作的眼部过敏性疾病，其特征表现为双侧眼表慢性炎症，若不及时干预，可导致眼表不可逆性损伤甚至失明。《亚洲春季角结膜炎的诊断、管理和治疗：亚洲春季角结膜炎管理专家工作组的建议》详细介绍了VKC的最新管理方法。本文就该共识进行全面解读，旨在进一步提高广大医务工作者诊断和治疗VKC的水平，以便更好地服务于广大眼病患者。
Abstract:
Vernal keratoconjunctivitis (VKC) is a recurrent ocular allergic disease characterized by chronic bilateral ocular surface inflammation, which can result in irreversible damage to the ocular surface and even blindness if not timely recognized and treated. Diagnosis, Management, and Treatment of Vernal Keratoconjunctivitis in Asia: recommendations from the Management of Vernal Keratoconjunctivitis in Asia Expert Working Group details the latest VKC management methods. This paper comprehensively interprets the consensus, aiming to improve VKC diagnosis and treatment levels among medical workers and serve eye disease patients better.

参考文献/References:

［1］　LEONARDI A.Management of vernal keratoconjunctivitis［J］.Ophthalmol Ther,2013,2(2):73-88.
［2］　BRUSCHI G,GHIGLIONI D G,OSNAGHI S,ROSAZZA C,MARAFON D P,LANDI M,et al.Role of ocular cytology in vernal keratoconjunctivitis［J］.Immun Inflamm Dis,2020,8(1):3-7.
［3］　ADDIS H,JENG B H.Vernal keratoconjunctivitis［J］.Clin Ophthalmol,2018,12:119-123.
［4］　HALL A,SHILIO B.Vernal keratoconjunctivitis［J］.Community Eye Health,2005,18(53):76-78.
［5］　BREMOND-GIGNAC D,DONADIEU J,LEONARDI A,POULIQUEN P,DOAN S,CHIAMBARRETTA F,et al.Prevalence of vernal keratoconjunctivitis:a rare disease［J］.Br J Ophthalmol,2008,92(8):1097-1102.
［6］　MIYAZAKI D,FUKAGAWA K,OKAMOTO S,FUKUSHIMA A,UCHIO E,EBIHARA N,et al.Epidemiological aspects of allergic conjunctivitis［J］.Allergol Int,2020,69(4):487-495.
［7］　ZICARI A M,CAPATA G,NEBBIOSO M,DE CASTRO G,MIDULLA F,LEONARDI L,et al.Vernal keratoconjunctivitis:an update focused on clinical grading system［J］.Ital J Pediatr,2019,45(1):64.
［8］　LEONARDI A.Vernal keratoconjunctivitis:pathogenesis and treatment［J］.Prog Retin Eye Res,2002,21(3):319-339.
［9］　SACCHETTI M,BAIARDINI I,LAMBIASE A,ARONNI S,FASSIO O,GRAMICCIONI C,et al.Development and testing of the quality of life in children with vernal keratoconjunctivitis questionnaire［J］.Am J Ophthalmol,2007,144(4):557-563.
［10］　KATELARIS C H.Ocular allergy in the Asia Pacific region［J］.Asia Pac Allergy,2011,1(3):108-114.
［11］　CAMERON J A.Shield ulcers and plaques of the cornea in vernal keratoconjunctivitis［J］.Ophthalmology,1995,102(6):985-993.
［12］　REDDY J C,BASU S,SABOO U,MURTHY S I,VADDAVALLI P K,SANGWAN V S.Management,clinical outcomes,and complications of shield ulcers in vernal keratoconjunctivitis［J］.Am J Ophthalmol,2013,155(3):550-559.
［13］　MEHTA J S,CHEN W L,CHENG A C K,CUNG LX,DUALAN I J,KEKUNNAYA R,et al.Diagnosis,management,and treatment of vernal keratoconjunctivitis in Asia:recommendations from the management of vernal keratoconjunctivitis in Asia expert working group［J］.Front Med (Lausanne),2022,9:882240.
［14］　MISHRA G P,TAMBOLI V,JWALA J,MITRA A K.Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis［J］.Recent Pat Inflamm Allergy Drug Discov,2011,5(1):26-36.
［15］　LEONARDI A,SILVA D,PEREZ FORMIGO D,BOZKURT B,SHARMA V,ALLEGRI P,et al.Management of ocular allergy［J］.Allergy,2019,74(9):1611-1630.
［16］　TAKAMURA E,UCHIO E,EBIHARA N,OHNO S,OHASHI Y,OKAMOTO S,et al.Japanese guidelines for allergic conjunctival diseases 2017［J］.Allergol Int,2017,66(2):220-229.
［17］　LEONARDI A,DOAN S,FAUQUERT J L,BOZKURT B,ALLEGRI P,MARMOUZ F,et al.Diagnostic tools in ocular allergy［J］.Allergy,2017,72(10):1485-1498.
［18］　LIU M,GAO H,WANG T,WANG S,LI S,SHI W.An essential role for dendritic cells in vernal keratoconjunctivitis:analysis by laser scanning confocal microscopy［J］.Clin Exp Allergy,2014,44(3):362-370.
［19］　BONINI S,SACCHETTI M,MANTELLI F,LAMBIASE A.Clinical grading of vernal keratoconjunctivitis［J］.Curr Opin Allergy Clin Immunol,2007,7(5):436-441.
［20］　SIMONS F E，SIMONS K J.The pharmacology and use of H1-receptor-antagonist drugs［J］.N Engl J Med,1994,330(23):1663-1670.
［21］　LEURS R,CHURCH M K,TAGLIALATELA M.H1-antihistamines:inverse agonism,anti-inflammatory actions and cardiac effects［J］.Clin Exp Allergy,2002,32(4):489-498.
［22］　刘昕.过敏性结膜炎药物治疗研究进展［J］.现代养生,2018,325(12):106-107.
LIU X.Progress in drug treatment of allergic conjunctivitis［J］.Health Prot Prom,2018,325(12):106-107.
［23］　GOKHALE N S.Systematic approach to managing vernal keratoconjunctivitis in clinical practice:severity grading system and a treatment algorithm［J］.Indian J Ophthalmol,2016,64(2):145-148.
［24］　MLLER G G,JOS N K,DE CASTRO R S,DE HOLANDA E C.Long-term use of topical tacrolimus ointment:a safe and effective option for the treatment of vernal keratoconjunctivitis［J］.Arq Bras Oftalmol,2019,82(2):119-123.
［25］　FUKUSHIMA A,OHASHI Y,EBIHARA N,UCHIO E,OKAMOTO S,KUMAGAI N,et al.Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement［J］.Br J Ophthalmol,2014,98(8):1023-1027.
［26］　PHULKE S,KAUSHIK S,KAUR S,PANDAV S S.Steroid-induced glaucoma:an avoidable irreversible blindness［J］.J Curr Glaucoma Pract,2017,11(2):67-72.
［27］　CALDERON M A,PENAGOS M,SHEIKH A,CANONICA G W,DURHAM S R.Sublingual immunotherapy for allergic conjunctivitis:cochrane systematic review and meta-analysis［J］.Clin Exp Allergy,2011,41(9):1263-1272.
［28］　LIN H Y,YEH P T,SHIAO C S,HU F R.Surgical management and immunohistochemical study of corneal plaques in vernal keratoconjunctivitis［J］.J Formos Med Assoc,2013,112(9):569-573.
［29］　PELEGRIN L,GRIS O,ADN A,PLAZAS A.Superficial keratectomy and amniotic membrane patch in the treatment of corneal plaque of vernal keratoconjunctivitis［J］.Eur J Ophthalmol,2008,18(1):131-133.
［30］　SOLOMON A,ZAMIR E,LEVARTOVSKY S,FRUCHT-PERY J.Surgical management of corneal plaques in vernal keratoconjunctivitis:a clinicopathologic study［J］.Cornea,2004,23(6):608-612.
［31］　STOCK R A,LAZZARI S L,MARTINS I P,BONAMINGO E L.Surgical debridement of corneal shield ulcers in pediatric patients:two case reports and a review of the literature［J］.J Med Case Rep,2020,14(1):70.
［32］　ALHARAN D H.Management of vernal keratoconjunctivitis in children in Saudi Arabia［J］.Oman J Ophthalmol,2020,13(1):3-12.

相似文献/References:

[1]何丽琴,邹晶,邵毅,等.春季角结膜炎活动期眼表和泪液蛋白的临床研究[J].眼科新进展,2015,35(12):1137.[doi:10.13389/j.cnki.rao.2015.0311]
　HE Li-Qin,ZOU Jing,SHAO Yi,et al.Clinical research on ocular surface condition and tear protein alteration in active vernal keratoconjunctivitis patients[J].Recent Advances in Ophthalmology,2015,35(3):1137.[doi:10.13389/j.cnki.rao.2015.0311]
[2]吴晓蓉,邹晶,邵毅,等.睑板下注射曲安奈德改善活动期春季角结膜炎患者眼表症状的临床研究[J].眼科新进展,2016,36(1):026.[doi:10.13389/j.cnki.rao.2016.0008]
　WU Xiao-Rong,ZOU Jing,SHAO Yi.HU Pei-Hong,et al.Clinical research on characteristics of tear film and tear protein after injection of triamcinolone under meibomian for active vernal keratoconjunctivitis patients[J].Recent Advances in Ophthalmology,2016,36(3):026.[doi:10.13389/j.cnki.rao.2016.0008]

备注/Memo

备注/Memo:
国家自然科学基金项目（编号:82160195）；中央引导地方科技发展资金项目（编号: 20211ZDG02003）
更新日期/Last Update: 2023-03-05